Building MOMENTUM for Patients with Myelofibrosis

Developing and commercializing targeted therapeutics to address serious unmet needs in oncology.

Sierra is currently awaiting topline results for its pivotal Phase 3 clinical study, MOMENTUM, a randomized double-blind trial for myelofibrosis patients who are symptomatic and anemic, and who have been treated previously with a JAK inhibitor.

Sierra is awaiting topline results for its pivotal Phase 3 clinical study, MOMENTUM, a randomized double-blind trial for myelofibrosis patients who are symptomatic and anemic, and who have been treated previously with a JAK inhibitor.

Recent News